Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose


The Purpose of this study is to compare the effects of 2 types of dietary fiber, psyllium and microcrystalline cellulose (MCC), on glycemic measures in subjects with impaired fasting glucose.

Full Title of Study: “A Randomized, Controlled Study To Compare the Effects of 2 Types of Dietary Fiber, Psyllium and Microcrystalline Cellulose, on Glycemic Measures in Subjects With Pre-type 2 Diabetes”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Single (Investigator)
  • Study Primary Completion Date: May 2013

Detailed Description

This study will be conducted at a single study center. Approximately 40 subjects with pre-type 2 diabetes will be enrolled and randomized in this study.

This 22-week study consists of 3 periods: an 8-week treatment period (Visits 2-4), a 6-week washout period, and an 8-week treatment period (Visits 5-7).


  • Dietary Supplement: psyllium
    • 1 level tablespoon (~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
  • Dietary Supplement: Microcrystalline Cellulose
    • 1 level tablespoon (~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day

Arms, Groups and Cohorts

  • Experimental: psyllium
    • 5.1 g psyllium husk in at least 8 ounces of water
  • Active Comparator: Microcrsytalline Cellulose
    • 1.18 g Microcrystalline Cellulose in at least 8 ounces of water, taken twice a day

Clinical Trial Outcome Measures

Primary Measures

  • fasting serum glucose
    • Time Frame: 8 weeks
    • mean change from baseline in fasting serum glucose at 8 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • be male or female,
  • at least 18 years of age
  • in generally good health for the pre-type 2 diabetes population;
  • if female, be postmenopausal or if of child-bearing capacity agree to use an adequate form of contraception
  • have not used any psyllium containing products within the past 3 months;
  • be willing to refrain from taking any psyllium containing products during the study;
  • be willing to maintain a lifestyle habits for the duration of the study;
  • have a fasting serum glucose of 110 – 125 mg/dL

Exclusion Criteria

  • if female, are pregnant or nursing (lactating);
  • have a history of diabetes (diagnosis) or is currently taking medications for diabetes
  • participated in a clinical drug study or used investigational drug during the previous 30 days;
  • have symptoms and signs suggestive of significant underlying disease, or acute onset of new symptoms and signs of major organ disease, that could become unstable during the trial requiring urgent medical intervention
  • have evidence of or treatment history of malignancy within the previous 5 years;
  • currently alcohol dependent;
  • used anti-psychotics in the previous 3 months;
  • used systemic steroidal agents within the last 30 days;
  • had used oral or systemic antibiotics or any over-the-counter (OTC) bactericidal medication (eg, bismuth salts) within the last 30 days;
  • has been taking any medication that may affect blood glucose or GI motility (eg, calcium channel blockers, beta blockers, antimuscarinics, salicylates etc.) for less than 30 days or 5 times the half life of the drug (need to be stable on the medication);
  • have evidence of immunodeficiency including subjects currently taking systemic corticosteroids or immunosuppressive drugs
  • have a major psychiatric disorder, including major depression, psychoses, alcohol or substance abuse within the past 2 years;
  • has a known sensitivity or allergy to any components of study products, including psyllium and aspartame (see Section 3.5.3);
  • were previously screened (ie, Visit 1 procedures) for participation in this study and failed to meet entry criteria;
  • have difficulty swallowing

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Procter and Gamble
  • Collaborator
    • Duke University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • John McRorie, PhD, Study Director, Procter and Gamble
    • Mark Feinglos, MD, Principal Investigator, Duke University
    • Richard Surwit, PhD, Principal Investigator, Duke University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.